Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.

Biology of the neonate2005Schmidt B

研究デザインレビュー

対象ヒト

抄録

cc by 以外（cc by-nc / cc by-nc-nd / NONE 等）は抄録を再掲しない。DOI/PMID へのリンクのみ表示する。

MeSH

AgingApneaBlindnessCerebral PalsyCognition DisordersDeafnessFollow-Up StudiesHumansInfant MortalityInfant, NewbornInfant, Premature, DiseasesPlacebosRandomized Controlled Trials as TopicRisk AssessmentTreatment OutcomeXanthines

DOI 10.1159/000087584

PMID 16210843

原文・出典を見る →